The wish list from business ahead of Rishi Sunak’s speech

As UK faces spiralling raw material costs, staff shortages, and rising energy prices, here is what CEOs want from chancellor

Smith & Nephew plc (SNN)

NYSE - Nasdaq Real-time price. Currency in USD

Add to watchlist

35.60-0.08 (-0.22%)

As of 12:57PM EDT. Market open.

Trade prices are not sourced from all markets

All

Simply Wall St.
Declining Stock and Decent Financials: Is The Market Wrong About Smith & Nephew plc (LON:SN.)?
Smith & Nephew (LON:SN.) has had a rough three months with its share price down 19%. But if you pay close attention...
Simply Wall St.
Estimating The Intrinsic Value Of Smith & Nephew plc (LON:SN.)
How far off is Smith & Nephew plc ( LON:SN. ) from its intrinsic value? Using the most recent financial data, we'll...
Motley Fool
Will a Powerful Acquisition Make This Early 2021 IPO a Buy?
Bioventus (NASDAQ: BVS) is a company that specializes in developing innovations in biologics and clinical therapies for active healing. In February of this year, Bioventus opened its doors of ownership to the public by way of an IPO of 8 million shares. Leading up to the spin-off, Smith & Nephew was experiencing strong growth from the biologics and clinical therapies unit, with annual revenue growing from $52 million in 2004 to $223 million in 2010 for that unit alone.